|
Masitinib Phase 3 Trial Data Show Slowed Amyotrophic Lateral Sclerosis Progression, A
Masitinib Phase 3 Trial Data Show Slowed Amyotrophic Lateral Sclerosis Progression, AB Science Says
ALS Progression Slowed by Masitinib, Phase 3 Clinical Study Data Show |
AB Science presents phase 3 data for masitinib in amyotrophic lateral sclerosis (ALS)
AB Science presents phase 3 data for masitinib in amyotrophic lateral sclerosis (ALS) at the European Network for the Cure of ALS (ENCALS) annual meeting
AB Science presents phase 3 data for masitinib in amyotrophic lateral sclerosis (ALS) at the European Network for the Cure of ALS (ENCALS) annual meeting – MilTech |
AB Science trumpets phase 3 ALS data, but investors seem unmoved
AB Science trumpets phase 3 ALS data, but investors seem unmoved
AB Science trumpets phase 3 ALS data, but investors seem unmoved | FierceBiotech |
| All times are GMT -5. The time now is 09:39 PM. |
Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.